Clinical trial
A Phase III Clinical Endpoint Evaluation Study Examining the Safety and Efficacy of HLD200 in Pediatric Subjects With Attention-Deficit Hyperactivity Disorder.
NCT02255513 is registered in ClinicalTrials.gov with Ironshore Pharmaceuticals and Development, Inc as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase III Clinical Endpoint Evaluation Study Examining the Safety and Efficacy of HLD200 in Pediatric Subjects With Attention-Deficit Hyperactivity Disorder.
- Lead sponsor
- Ironshore Pharmaceuticals and Development, Inc
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- May 31, 2014
- Completion date
- October 31, 2014
- Enrollment
- 43 (actual)
- Sites
- 4
Conditions
As the registry lists them; a condition with its own page is linked.
attention deficit hyperactivity disorder